Cancer-associated thrombosis

cancer-associated-thrombosis

← back to Hematology & Oncology

Summary

The 2022 ITAC international clinical practice guidelines provide GRADE-based recommendations for treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer, including those with COVID-19. This update incorporates new RCT evidence supporting direct oral anticoagulants (DOACs) as first-line options alongside LMWH for cancer-associated thrombosis, addresses primary prophylaxis with DOACs in ambulatory patients with elevated Khorana scores, and adds new guidance for cancer patients with COVID-19.

Current guideline: ITAC 2022 Cancer-Associated Thrombosis Guideline · download Anki sub-deck

Versions

Table of contents